SOUT posted earnings on August 15. I am beginning to anticipate November 15 already.
What we know:
- Sevoflurane is the most widely used inhalable anesthetic gas in the world.
- The price of Sevoflurane has not suffered significant erosion as it became generic.
- SOUT is on target with their distribution of Sevoflurane in capturing the projected 11 to 15 percent of the market in the U.S.
SOUT has sales agreements in place with the hospitals who purchase Sevoflurane
The Sevoflurane revenue stream should be well established this quarter and revenue should reflect that.
Clearly, now is the time to buy before news moves this stock.
This is a generic drug company with a pipeline of generic drugs that have a high barrier to entry due to the complexity of the manufacturing process. See BLOGS!
This is a company that retired $16M in debt. Listen to Interview of CEO, Johnathan Houssian, for details!
- SOUT Interview with CEO MP3:
http://www.stockguru.com/audio/sout10022007.mp3 - SOUT Interview with CEO Windows Media:
http://www.stockguru.com/audio/sout10022007.wma
RxElite has agreements with over ninety percent of the U.S. market for generic drugs. These agreements represent 50 of the top 75 generic drug buyers. See Profile.
Power Point for Investor Profile from Rx Elite
Source: RxElite Holdings, Inc.
RxElite Holdings, Inc.
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191 Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
Segue Ventures LLCAbout RxElite Holdings, Inc.: RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Disclosure: Pentony Enterprises LLC was compensated $18,000.00. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC,9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com.